SCHEMBL30201178

SCHEMBL30201178

CC1CN(C(=O)c2cnc3c(ccn3-c3ccc(-c4ncn[nH]4)nc3)c2)CC(C)O1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.42
NPC1 O15118 2/20 0.39
HSD17B10 Q99714 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MGLL Q99685 1/20 0.38
ALDH1A1 P00352 4/20 0.36
VNN1 O95497 1/20 0.36
FGFR1 P11362 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR3 P22607 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
RAB9A P51151 1/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30201388 0.92 HPGD (0.41) HPGDNPSR1MGLLVNN1EGLN1
SCHEMBL24942672 0.88 HPGD (0.42) HPGDNPC1MGLLALDH1A1RAB9A
SCHEMBL24942782 0.86 HPGD (0.44) HPGDMGLLVNN1EGLN1
SCHEMBL24942242 0.85 HPGD (0.58) HPGDMGLLALDH1A1EGLN1
SCHEMBL24942671 0.84 HPGD (0.47) HPGDMGLLVNN1
SCHEMBL24942655 0.84 HPGD (0.44) HPGDMGLLALDH1A1VNN1EGLN1
SCHEMBL24942785 0.84 HPGD (0.41) HPGDMGLLVNN1
SCHEMBL24942662 0.83 HPGD (0.47) HPGDHSD17B10MGLLALDH1A1VNN1
SCHEMBL24942663 0.83 HPGD (0.43) HPGDMGLLVNN1RAB9A
SCHEMBL23680808 0.82 HPGD (0.46) HPGDMGLLVNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294519-A1 PYRROLO[2,3-b]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING EPIRIUM BIO INC. 2024-09-05 US disclosed
CN-118338902-A Pyrrolo [2,3-b ] pyridine PGDH inhibitors and methods of making and using the same 埃皮里姆生物股份有限公司 2024-07-12 CN disclosed
EP-4376841-A1 PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING Epirium Bio Inc. (US) 2024-06-05 EP disclosed
WO-2023009642-A1 PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING EPIRIUM BIO INC. (US) 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294519-A1 PYRROLO[2,3-b]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING HPGD, HPGDS, PTGIS HPGD 1/4885NPC1 2754/4885HSD17B10 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.